Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

NCT02298933 | Completed Phase 2 Results DMC FDA Drug

• 2 other identifiers: 15001515-H-0015
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Background: \- Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets. Getting a transfusion of another person s platelets can help stop too much bleeding. But because these cells are from other people, the body may reject them,putting them at risk for serious bleeding complications. This conditions is called alloimmune platelet refractoriness . There are evidence that in many patients, platelet counts fail to increase after a platelet transfusion because the transfused platelets are destroyed by the body s defence soldier, called complement . Researchers want to see if a drug, that inhibits complement, can help increase platelet levels and reduce bleeding Objectives: \- To see if eculizumab increases platelet levels more after a transfusion. To see if it reduces the chance of bleeding too much. Eligibility: \- Adults 18-75 years old who have thrombocytopenia and alloimmune platelet refractoriness. Design:

• Participants will be screened with medical history, physical exam, and blood tests.
• Participants will have the procedures listed below. They can have them while they are in the hospital. Or they can go to the outpatient clinic for them. Each visit may take up to 3 hours.
• Participants will get a meningitis vaccine if needed. Then they will get the study drug as an infusion.
• Participants will have a platelet transfusion. Their blood will be drawn every 24 hours until the platelet count is less than 10,000 per 1 microliter of blood.
• They will take antibiotics for 14 days.
• Participants will have a checkup and blood drawn twice a week for 2 weeks. They will get more transfusions if needed.

Conditions

Thrombocytopenia; Alloimmune Platelet Refractoriness

Keywords

Complement Inhibition; Platelet Refractoriness; Eculizumab

Outcome Measures

Primary Outcomes (1)

• Number of Subjects With Sustained Platelet Transfusion Responsiveness

  To evaluate the safety and efficacy of eculizumab to increase the platelet increment, defined as Corrected Count Increment (CCI) \>7500/μL at 10-60 min together with CCI\>5000/μL at 18-24 hrs post transfusion in patients with platelet refractoriness following treatment with eculizumab and platelet transfusion.

  24 hours

Study Arms (1)

Eculizumab

EXPERIMENTAL

1200 mg IV infusion over 30-40 min

Drug: Eculizumab

Interventions

Eculizumab DRUG

300 mg single-use vials

Eculizumab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ages 18-75 years inclusive.
• Ability to comprehend the investigational nature of the study and provide informed consent.
• Thrombocytopenia (due to congenital causes, bone marrow failure, hematologic malignancies, and treatment related), defined as \<10k/uL without bleeding or \<30K/uL with evidence of life threatening bleeding (intracranial hemorrhage, GI bleeding, pulmonary hemorrhage, uncontrolled epistaxis, hematuria).
• Diagnosed with immune platelet refractoriness, characterized by all of the following:
• Lack of adequate post-transfusion platelet count increment, defined by, CCI \<7500/ul at 10-60 min, and CCI \<5000/ul at 18-24 hrs (in those who had a CCI at 10-60 min greater than or equal to 5000/microl)after at least 2 consecutive transfusions.
• Presence of anti-HLA class A and/or B antibody.

You may not qualify if:

• Active meningococcal infection.
• Severe psychiatric illness. Mental deficiency sufficiently severe as to make making informed consent impossible.
• Positive pregnancy test for women of childbearing age within 1 week.
• HIV positive test within 3 months
• Paroxysmal Nocturnal Hemoglobinuria (PNH) disease with evidence of intravascular hemolysis.
• Presence ITP/autoimmune thrombocytopenia
• Immune platelet refractoriness responsive to treatment with IVIG
• RE-ENROLLMENT CRITERIA:
• Meet response criteria to the initial treatment or second treatment

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

• Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020 May;189(3):551-558. doi: 10.1111/bjh.16385. Epub 2020 Feb 21.

  PMID: 32086819 DERIVED

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Thrombocytopenia

Interventions

eculizumab

Condition Hierarchy (Ancestors)

Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Cytopenia

Results Point of Contact

• Title: Aue, Georg
• Organization: National Heart Lung and Blood Institute

aueg@nhlbi.nih.gov

+1 301 451 7141

Study Officials

• Georg Aue, M.D.

  National Heart, Lung, and Blood Institute (NHLBI)

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2014
• First Posted: November 24, 2014
• Study Start: November 21, 2014
• Primary Completion: August 8, 2017
• Study Completion: August 8, 2017
• Last Updated: January 3, 2019
• Results First Posted: January 3, 2019

Record last verified: 2018-01-18

Locations

US (1)